The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The value of combining acalabrutinib with chemoimmunotherapy in patients with R/R DLBCL
Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, comments on the potential value of combining BTK inhibitors with chemoimmunotherapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), highlighting high complete response (CR) rates and improved long-term outcomes for patients who received a regimen of acalabrutinib and chemoimmunotherapy prior to undergoing transplant. Dr Patel notes that this approach could hold value as an alternative therapeutic strategy for patients who may not have access to novel treatments like CAR-T or bispecific antibodies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We conducted a study now some years ago looking at the combination of acalabrutinib with chemoimmunotherapy for patients who are receiving second-line treatment with relapsed large cell lymphoma. That was the standard of care when we started that study almost five years ago, and I think what we wanted to really kind of present in terms of the data now is that, when we think about disease control for large cell lymphoma, the incorporation of novel therapies can really be an interesting way to, I think, improve outcomes for patients that may not have access to treatments like CAR T-cells or bispecific antibodies...
We conducted a study now some years ago looking at the combination of acalabrutinib with chemoimmunotherapy for patients who are receiving second-line treatment with relapsed large cell lymphoma. That was the standard of care when we started that study almost five years ago, and I think what we wanted to really kind of present in terms of the data now is that, when we think about disease control for large cell lymphoma, the incorporation of novel therapies can really be an interesting way to, I think, improve outcomes for patients that may not have access to treatments like CAR T-cells or bispecific antibodies. Drugs like acalabrutinib are available globally. And so I think the takeaways of the study are that combination of BTK inhibitor in large cell lymphoma may have some value in certain settings, may not be the way forward in a lot of countries, but I think there was a really interesting signal there, high CR rates, very good long-term outcomes for patients who were undergoing transplant and compared to historical norms, much better outcomes for those patients with the inclusion of acalabrutinib.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sunesis Pharmaceuticals: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Morphosys: Consultancy; AbbVie: Consultancy; Adaptive Biotechnologies: Research Funding; Nurix: Research Funding; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Epizyme: Consultancy, Research Funding; Curis, Inc: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; ADC Therapeutics: Consultancy; Xencor: Consultancy, Research Funding; BeiGene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy.
